Vigilant Capital Management, LLC Biogen Inc. Transaction History

Vigilant Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 07, 2022	SELL	$193.77 - $244.14 $19,377 - $24,414	-100 Closed	0 $0
Q4 2021 Jan 06, 2022	BUY	$223.92 - $287.77 $22,392 - $28,777	100 New	100 $24,000
Q4 2020 Jan 14, 2021	SELL	$236.26 - $355.63 $70,878 - $106,689	-300 Closed	0 $0
Q3 2020 Oct 15, 2020	BUY	$264.77 - $305.71 $79,431 - $91,713	300 New	300 $85,000
Q3 2019 Oct 16, 2019	SELL	$217.44 - $243.88 $35,007 - $39,264	-161 Closed	0 $0
Q2 2019 Jul 18, 2019	SELL	$219.29 - $241.72 $8.6 Million - $9.48 Million	-39,225 Reduced 99.59%	161 $38,000
Q1 2019 Apr 09, 2019	BUY	$216.71 - $338.96 $747,649 - $1.17 Million	3,450 Added 9.6%	39,386 $9.31 Million
Q4 2018 Jan 15, 2019	BUY	$278.5 - $352.75 $9.95 Million - $12.6 Million	35,714 Added 16087.39%	35,936 $10.8 Million
Q1 2018 Apr 04, 2018	BUY	$260.13 - $367.91 $44,482 - $62,912	171 Added 335.29%	222 $61,000
Q4 2017 Jan 31, 2018	BUY	$307.64 - $344.58 $15,689 - $17,573	51	51 $16,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Vigilant Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Vigilant Capital Management, LLC with notifications on news.